Aquestive Therapeutics Inc.

2.39+0.1400+6.22%Vol 970.55K1Y Perf 140.69%
Dec 1st, 2023 16:00 DELAYED
BID2.35 ASK2.45
Open2.35 Previous Close2.25
Pre-Market- After-Market2.45
 - -  0.06 2.46%
Target Price
6.38 
Analyst Rating
Strong Buy 1.00
Potential %
166.95 
Finscreener Ranking
★★★+     51.56
Insiders Trans % 3/6/12 mo.
100/100/100 
Value Ranking
     38.90
Insiders Value % 3/6/12 mo.
100/100/100 
Growth Ranking
★+     41.60
Insiders Shares Cnt. % 3/6/12 mo.
100/100/100 
Income Ranking
 —    -
Price Range Ratio 52W %
84.77 
Earnings Rating
Strong Buy
Market Cap159.57M 
Earnings Date
6th Nov 2023
Alpha-0.01 Standard Deviation0.33
Beta2.61 

Today's Price Range

2.262.48

52W Range

0.72002.69

Summary:

Buy

Technical Indicators: Neutral
Moving Averages: Strong Buy
Performance
1 Week
12.74%
1 Month
65.97%
3 Months
43.11%
6 Months
5.75%
1 Year
140.69%
3 Years
-64.43%
5 Years
-72.18%
10 Years
-

TickerPriceChg.Chg.%
AQST2.390.14006.22
AAPL191.241.29000.68
GOOG133.32-0.6000-0.45
MSFT374.51-4.4000-1.16
XOM102.990.25000.24
WFC45.020.43000.96
JNJ158.383.72002.41
FB196.640.99000.51
GE122.500.70000.57
JPM156.840.76000.49
ProfitabilityValueIndustryS&P 500US Markets
63.70
-117.90
-112.20
-122.70
-91.51
RevenueValueIndustryS&P 500US Markets
37.00M
0.68
-3.11
-6.32
Earnings HistoryEstimateReportedSurprise %
Q03 2023-0.11-0.0372.73
Q02 2023-0.11-0.109.09
Q01 2023-0.100.11210.00
Q04 2022-0.21-0.23-9.52
Q03 2022-0.30-0.2323.33
Q02 2022-0.41-0.3612.20
Q01 2022-0.45-0.3228.89
Q04 2021-0.37-0.38-2.70
Earnings Per EndEstimateRevision %Trend
12/2023 QR-0.0855.56Positive
12/2023 FY-0.0772.00Positive
3/2024 QR-0.1016.67Positive
12/2024 FY-0.3439.29Positive
Next Report Date-
Estimated EPS Next Report-0.11
Estimates Count3
EPS Growth Next 5 Years %-
Volume Overview
Volume970.55K
Shares Outstanding66.77K
Shares Float61.17M
Trades Count3.19K
Dollar Volume2.31M
Avg. Volume362.34K
Avg. Weekly Volume525.24K
Avg. Monthly Volume314.19K
Avg. Quarterly Volume247.58K

Aquestive Therapeutics Inc. (NASDAQ: AQST) stock closed at 2.39 per share at the end of the most recent trading day (a 6.22% change compared to the prior day closing price) with a volume of 970.55K shares and market capitalization of 159.57M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 232 people. Aquestive Therapeutics Inc. CEO is Keith J. Kendall.

The one-year performance of Aquestive Therapeutics Inc. stock is 140.69%, while year-to-date (YTD) performance is 164.94%. AQST stock has a five-year performance of -72.18%. Its 52-week range is between 0.72 and 2.69, which gives AQST stock a 52-week price range ratio of 84.77%

Aquestive Therapeutics Inc. currently has a PE ratio of -0.50, a price-to-book (PB) ratio of 14.15, a price-to-sale (PS) ratio of 1.36, a price to cashflow ratio of 38.20, a PEG ratio of -, a ROA of -121.23%, a ROC of -107.70% and a ROE of 84.44%. The company’s profit margin is -91.51%, its EBITDA margin is -112.20%, and its revenue ttm is $37.00 Million , which makes it $0.68 revenue per share.

Of the last four earnings reports from Aquestive Therapeutics Inc., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.11 for the next earnings report. Aquestive Therapeutics Inc.’s next earnings report date is -.

The consensus rating of Wall Street analysts for Aquestive Therapeutics Inc. is Strong Buy (1), with a target price of $6.38, which is +166.95% compared to the current price. The earnings rating for Aquestive Therapeutics Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Aquestive Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Aquestive Therapeutics Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 18.44, ATR14 : 0.15, CCI20 : 162.77, Chaikin Money Flow : 0.19, MACD : 0.18, Money Flow Index : 88.67, ROC : 42.26, RSI : 74.25, STOCH (14,3) : 90.32, STOCH RSI : 1.00, UO : 58.93, Williams %R : -9.68), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Aquestive Therapeutics Inc. in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
4 (100.00 %)
4 (100.00 %)
4 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

Aquestive Therapeutics Inc.

Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. The product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS). Its commercial product portfolio includes Sympazan Oral Film, Suboxone Sublingual Film, and Zuplenz. The products pipeline includes Exservan Oral Film, Libervant Buccal Film, AQST-119, AQST-108, and AQST-305.

CEO: Keith J. Kendall

Telephone: +1 908 941-1900

Address: 30 Technology Drive, Warren 07059, NJ, US

Number of employees: 232

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

50%50%

Bearish Bullish

58%42%

Bearish Bullish

56%44%

 

TipRanks News for AQST

Tue, 10 Oct 2023 11:01 GMT Analysts Top Healthcare Picks: Aquestive Therapeutics (AQST), Guardant Health (GH)

- TipRanks. All rights reserved.

Wed, 20 Sep 2023 19:52 GMT Setback for Neffy unlikely to affect Aquestives Anaphylm, says Alliance Global

- TipRanks. All rights reserved.

Tue, 08 Aug 2023 15:25 GMT Aquestive Therapeutics (AQST) Receives a Buy from JMP Securities

- TipRanks. All rights reserved.

News

Stocktwits